Loading…
← CockpitCompetitor Analysis › RPRX Royalty Pharma Plc Class AOpen in the cockpit ↗

Royalty Pharma Plc Class ARPRXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Buys royalty streams on approved and pipeline biopharma drugs, collecting a cut of sales without doing R&D itself.

Momentum leader 88
Mkt cap
$39.4B
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$233M
20-day average traded
Fwd P/E
11.5×
forward earnings
ROIC−WACC
+0.7 pp
WACC 6.6%
Hurdle
+9 pp
Req g minus delivered
Official | Implied
BBB / A-
agencies · bond market
Next earnings
90 days
16 Feb 2027
Close · USD$68.67
1D0.0%
1W-1.9%
1M+10.3%
3M+13.3%
6M+29.4%
YTD+77.7%
1Y+75.4%
ATR %2.2%
Beta0.24
52w lowhigh2.4% off high

What Royalty Pharma does

Buys royalty streams on approved and pipeline biopharma drugs, collecting a cut of sales without doing R&D itself.

Pays upfront to buy a share of a drug's future sales, then collects a percentage of those sales for years, so income follows how well other companies' drugs sell. Its largest streams come from a few big drugs, notably the cystic fibrosis medicines sold by Vertex, a royalty it bought from the Cystic Fibrosis Foundation in 2014.

Products and services

  • Approved-drug royalty portfolio
  • Development-stage/synthetic royalty deals

Customers

  • Biotech/pharma companies (royalty sellers)
  • Academic institutions/inventors

Where it sits in the supply chain

  • Pharmaceuticals
  • Biopharma royalty finance
  • Royalty acquisition/licensing

What could go right

  • Growing pool of biotech royalty-monetization candidates
  • Royalty income growing with underlying drug sales

What could go wrong

  • Concentration in a handful of large royalty streams
  • Patent expiry/generic entry on royalty-bearing drugs

Moat: narrow (scale, distribution). Large capital base and industry relationships let it win bigger royalty deals than smaller rivals.

Headquarters: London, United Kingdom · Founded: 1996 · Employees: 100

Named competitors

Royalty Pharma at a glance

Size Royalty Pharma (RPRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $39.4B, the 300th largest of 3,085 United States companies the cockpit tracks. Shares closed at $68.67 on 18 Nov 2026.

Performance Over six months the shares gained 29.4%, against +13.3% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 11.3% over the last twelve months (peer median +16.4%); the operating margin is 65.5% (peer median 17.8%).

Valuation It trades at 11.5× forward earnings against a peer median of 19.0× (2nd cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.7 points above its cost of capital (6.6% WACC).

Credit Royalty Pharma has 11 bonds outstanding ($7.80B), rated BBB by the agencies and trading like A- at a weighted spread of 96 bp.

Short interest Short interest is 2.9% of the free float (30 Oct 2026).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026RPRX 128Peer median 115
Six months, rebased to 100: Royalty Pharma against the median of its 20 peers (local-currency closes).

Royalty Pharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.62B$2.38B$2.26B$2.35B$2.24B
Revenue growth—+5%-4%+5%—
Gross profit$2.61B$2.37Bn/an/a$2.23B
EBITDA$1.72B$1.56B$1.29B$1.49B$929M
Net income$671M$771M$859M$1.13B$42.8M
Free cash flow$2.99B$2.59B$2.79B$3.03B$2.14B
Capital expenditure$1.72B$1.70B$2.52B$2.12B$1.76B
Total debt$8.59B$8.97B$7.61B$6.14B$7.12B

Quarterly statements and history in the cockpit →

Royalty Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%+20%HLN4578SDZBIIBZTS1276688235SUNPHARMA45034568DIVISLABGALDROIVINSMBAYN2359INCYVTRSSIGRPRX6-month return →1-month return →
Up and to the right = strong over both horizons. Royalty Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%20×40×60×HLN4578SDZZTS1276688235SUNPHARMADIVISLABGALD36922359VTRSSIGRPRXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Royalty Pharma is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%+80%0%25%50%75%HLN4578SDZBIIBZTS688235SUNPHARMA45034568DIVISLABGALDINCYSIGRPRXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Royalty Pharma is the large dot.

Royalty Pharma competitors and peer comparison

Head to head with its named competitors (RPRX vs LGND vs INVA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Royalty Pharma RPRX$39.4B+29%+11%66%11.5×10.8%
Ligand Pharmaceuticals LGND$5.98B+37%+1%14%27.3×57.7%
Innoviva INVA$1.31B-17%+12%38%9.5×-17.2%

How Royalty Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Royalty Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureRPRXPeer medianRank in peer set
1-month return+10.3%+5.0%6th highest of 21
6-month return+29.4%+13.3%5th highest of 21
Distance from 52-week high-2.4%-9.1%2nd highest of 21
Revenue growth (TTM)+11.3%+16.4%8th lowest of 21
Operating margin65.5%17.8%highest of 21
Forward P/E11.5×19.0×2nd cheapest of 19
Growth the price implies (Req g, 7 yrs)10.8%9.1%8th most demanding of 18
Growth delivered (Del g)+2.3%+10.8%5th lowest of 18
Hurdle (Req g minus delivered)+8.5 pp+2.8 pp5th most demanding of 18
ROIC minus cost of capital+0.7 pp+4.8 pp8th lowest of 21
EV / EBITDA29.3×18.9×5th most expensive of 17
Net debt / EBITDA4.7×0.8×most indebted of 17
Bond spread96 bp100 bp4th tightest of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Jiangsu Hengrui Pharmaceuticals 1276.HKHong Kong$44.9B-24%+11%27%28.1×9.1%+2.0%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%12.9×-9.0%+11.4%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%18.4×7.6%+17.1%
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%73.5×47.1%+8.9%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%n/an/an/a
Insmed INSMUnited States$26.3B+3%+240%-42%n/an/an/a
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%25.8×7.9%+10.8%
Wuxi Apptec 2359.HKHong Kong$64.1B+51%+38%44%19.5×8.4%+20.4%
Incyte INCYUnited States$24.0B+21%+25%12%15.1×14.2%+14.0%
Viatris VTRSUnited States$23.3B+23%+5%11%7.5×11.2%+3.7%
Sigma Healthcare SIG.AXAustralia$22.4B+2%+209%9%38.4×28.9%+26.1%

Royalty Pharma bonds and credit

Royalty Pharma has 11 bonds outstanding with $7.80B face value. The agencies rate it BBB; its bonds trade like A-. Weighted yield 5.86%, a spread of 96 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Royalty Pharma's main competitors?
Named competitors: Ligand Pharmaceuticals (LGND), PDL BioPharma (private or unlisted), DRI Healthcare (private or unlisted), Innoviva (INVA), XOMA Royalty (private or unlisted). The cockpit's measured peer set (industry) also includes Haleon (HLN.L), Otsuka Hldgs (4578.T), Sandoz (SDZ.SW), Biogen (BIIB), Zoetis (ZTS), Jiangsu Hengrui Pharmaceuticals (1276.HK).
Is Royalty Pharma expensive compared with its peers?
On forward p/e it trades at 11.5× against a peer median of 19.0×, 2nd cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Royalty Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +29.4% against +13.3% for the median peer; over one year +75.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.